Calliditas Therapeutics AB (publ) (CALT) Short Interest Ratio & Short Volume → Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad) Free CALT Stock Alerts $22.15 -0.04 (-0.18%) (As of 01:41 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Calliditas Therapeutics AB (publ) Short Interest DataCurrent Short Interest8,700 sharesPrevious Short Interest7,100 sharesChange Vs. Previous Month+22.54%Dollar Volume Sold Short$168,867.00Short Interest Ratio1.4 Days to CoverLast Record DateApril 30, 2024Outstanding Shares29,790,000 sharesPercentage of Shares Shorted0.03%Today's Trading Volume4,774 sharesAverage Trading Volume6,975 sharesToday's Volume Vs. Average68% Short Selling Calliditas Therapeutics AB (publ) ? Sign up to receive the latest short interest report for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCALT Short Interest Over TimeCALT Days to Cover Over TimeCALT Percentage of Float Shorted Over Time Ad Stansberry ResearchEverybody laughed when he recommended Netflix"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade. Calliditas Therapeutics AB (publ) Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20248,700 shares $168,867.00 +22.5%N/A1.4 $19.41 4/15/20247,100 shares $134,545.00 +121.9%N/A1 $18.95 3/31/20243,200 shares $67,232.00 -56.2%N/A0.4 $21.01 3/15/20247,300 shares $163,958.00 +15.9%N/A0.5 $22.46 2/29/20246,300 shares $134,312.85 +37.0%N/A0.4 $21.32 2/15/20244,600 shares $94,668.00 -20.7%N/A0.3 $20.58 Get the Latest News and Ratings for CALT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter. 1/31/20245,800 shares $132,588.00 No ChangeN/A0.4 $22.86 1/15/20245,800 shares $145,000.00 -43.1%N/A0.4 $25.00 12/31/202310,200 shares $262,588.80 +20.0%N/A0.6 $25.74 12/15/20238,500 shares $187,765.00 -29.2%N/A0.6 $22.09 11/30/202312,000 shares $208,200.00 +26.3%N/A1.1 $17.35 11/15/20239,500 shares $161,215.00 +93.9%N/A0.9 $16.97 10/31/20234,900 shares $79,870.00 +63.3%N/A0.5 $16.30 10/15/20233,000 shares $52,050.00 -21.1%N/A0.3 $17.35 9/30/20233,800 shares $69,388.00 +40.7%N/A0.4 $18.26 9/15/20232,700 shares $43,104.42 -34.2%N/A0.3 $15.96 8/31/20234,100 shares $72,652.00 -48.1%N/A0.6 $17.72 8/15/20237,900 shares $152,707.00 +315.8%N/A1.1 $19.33 7/31/20231,900 shares $37,050.00 -24.0%N/A0.3 $19.50 7/15/20232,500 shares $40,125.00 +4.2%N/A0.4 $16.05 6/30/20232,400 shares $37,680.00 -51.0%N/A0.4 $15.70 6/15/20234,900 shares $89,363.75 -41.7%N/A0.8 $18.24 5/31/20238,400 shares $143,304.00 +47.4%N/A0.8 $17.06 5/15/20235,700 shares $145,350.00 +128.0%N/A0.5 $25.50 4/30/20232,500 shares $58,350.00 -77.3%N/A0.2 $23.34 4/15/202311,000 shares $272,250.00 -16.0%N/A0.8 $24.75 3/31/202313,100 shares $314,007.00 -42.3%N/A0.9 $23.97 3/15/202322,700 shares $572,948.00 +58.7%N/A1.6 $25.24 2/28/202314,300 shares $264,693.00 +346.9%N/A1.4 $18.51 2/15/20233,200 shares $57,472.00 +10.3%N/A0.3 $17.96 1/31/20232,900 shares $55,680.00 -52.5%N/A0.3 $19.20 1/15/20236,100 shares $120,780.00 -38.4%N/A0.6 $19.80 12/30/20229,900 shares $168,300.00 +67.8%N/A0.9 $17.00 12/15/20225,900 shares $115,616.40 -38.5%N/A0.5 $19.60 11/30/20229,600 shares $174,432.00 +37.1%N/A0.8 $18.17 11/15/20227,000 shares $115,500.00 +25.0%N/A0.7 $16.50 10/31/20225,600 shares $83,440.00 +60.0%N/A0.6 $14.90 10/15/20223,500 shares $54,600.00 -59.3%N/A0.4 $15.60 9/30/20228,600 shares $130,428.46 +230.8%N/A1.4 $15.17 9/15/20222,600 shares $41,106.00 -27.8%N/A0.5 $15.81Does this make you sick? (Ad)The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit 8/31/20223,600 shares $59,400.00 -49.3%N/A0.8 $16.50 8/15/20227,100 shares $153,005.00 +4.4%N/A1.4 $21.55 7/31/20226,800 shares $126,820.00 -9.3%N/A1 $18.65 7/15/20227,500 shares $135,900.00 -22.7%N/A1.1 $18.12 6/30/20229,700 shares $172,175.00 -29.2%N/A1.3 $17.75 6/15/202213,700 shares $238,838.95 -19.9%N/A1.7 $17.43 5/31/202217,100 shares $305,235.00 -59.6%N/A1.8 $17.85 5/15/202242,300 shares $599,391.00 -34.0%N/A3.6 $14.17 4/30/202264,100 shares $942,911.00 -6.6%N/A5.7 $14.71 4/15/202268,600 shares $1.26 million -6.7%N/A4.1 $18.31 3/31/202273,500 shares $1.41 million -3.4%N/A3.4 $19.14 3/15/202276,100 shares $1.27 million +4.3%N/A2.1 $16.74 2/28/202273,000 shares $1.44 million +22.1%N/A0.4 $19.75 2/15/202259,800 shares $1.31 million -10.3%N/A0.3 $21.85 1/31/202266,700 shares $1.41 million -25.0%N/A0.4 $21.21 1/15/202288,900 shares $2.06 million +51.2%N/A0.5 $23.17 12/31/202158,800 shares $1.46 million -41.7%N/A0.3 $24.76 12/15/2021100,800 shares $1.88 million +94.2%N/A0.6 $18.64 11/30/202151,900 shares $954,441.00 +25.7%N/A1.4 $18.39 11/15/202141,300 shares $707,882.00 -29.3%N/A1.1 $17.14 10/29/202158,400 shares $953,088.00 +11.9%N/A1.4 $16.32 10/15/202152,200 shares $1.16 million +26.1%N/A1.6 $22.18 9/30/202141,400 shares $895,068.00 -56.0%N/A1.3 $21.62 9/15/202194,000 shares $2.13 million +67.0%N/A3 $22.71 8/31/202156,300 shares $1.59 million +50.1%N/A2.3 $28.18 8/13/202137,500 shares $1.13 million -18.7%N/A2 $30.15 7/30/202146,100 shares $1.34 million -3.0%0.2%3.5 $29.05 7/15/202147,500 shares $1.39 million +5.1%0.2%1.8 $29.20 6/30/202145,200 shares $1.33 million -12.2%0.2%1.4 $29.45 6/15/202151,500 shares $1.56 million -8.5%0.2%1.4 $30.39 5/28/202156,300 shares $1.67 million -0.5%0.2%1.5 $29.60 5/14/202156,600 shares $1.53 million +55.9%0.2%1.5 $27.12 4/30/202136,300 shares $1.08 million +58.5%0.2%0.9 $29.64 4/15/202122,900 shares $617,155.00 No Change0.1%0.6 $26.95 3/31/202122,900 shares $628,834.00 -4.6%0.1%0.7 $27.46 3/15/202124,000 shares $718,560.00 +211.7%0.1%1 $29.94 2/26/20217,700 shares $222,068.00 +102.6%0.0%0.3 $28.84 2/12/20213,800 shares $121,828.00 -24.0%0.0%0.2 $32.06 1/29/20215,000 shares $140,700.00 +11.1%0.0%0.1 $28.14 1/15/20214,500 shares $140,085.00 No Change0.0%0.1 $31.13 CALT Short Interest - Frequently Asked Questions What is Calliditas Therapeutics AB (publ)'s current short interest? Short interest is the volume of Calliditas Therapeutics AB (publ) shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 8,700 shares of CALT short. Learn More on Calliditas Therapeutics AB (publ)'s current short interest. What is a good short interest ratio for Calliditas Therapeutics AB (publ)? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CALT shares currently have a short interest ratio of 1.0. Learn More on Calliditas Therapeutics AB (publ)'s short interest ratio. Which institutional investors are shorting Calliditas Therapeutics AB (publ)? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Calliditas Therapeutics AB (publ): Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Calliditas Therapeutics AB (publ)'s short interest increasing or decreasing? Calliditas Therapeutics AB (publ) saw a increase in short interest in April. As of April 30th, there was short interest totaling 8,700 shares, an increase of 22.5% from the previous total of 7,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Calliditas Therapeutics AB (publ)'s short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Calliditas Therapeutics AB (publ): GH Research PLC (5.05%), AnaptysBio, Inc. (18.06%), CureVac (4.79%), Pharming Group (0.01%), Mineralys Therapeutics, Inc. (4.46%), Lyell Immunopharma, Inc. (16.91%), Cogent Biosciences, Inc. (12.59%), Savara Inc (6.37%), Silence Therapeutics plc (0.99%), Wave Life Sciences Ltd. (2.27%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Calliditas Therapeutics AB (publ) stock? Short selling CALT is an investing strategy that aims to generate trading profit from Calliditas Therapeutics AB (publ) as its price is falling. CALT shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Calliditas Therapeutics AB (publ)? A short squeeze for Calliditas Therapeutics AB (publ) occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CALT, which in turn drives the price of the stock up even further. How often is Calliditas Therapeutics AB (publ)'s short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CALT, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: GHRS Short Squeeze ANAB Short Squeeze CVAC Short Squeeze PHAR Short Squeeze MLYS Short Squeeze LYEL Short Squeeze COGT Short Squeeze SVRA Short Squeeze SLN Short Squeeze WVE Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CALT) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsThis Could be Your “Big Money” AI MomentInvestorPlaceDigitizing the $11T commodities sector with one tiny stockResource Stock DigestObama’s Forever Term [exposed]Porter & CompanyNew Options need New Trading StrategiesNetpicks